Computer-aided drug design of pyranopyrazoles and related compounds for checkpoint kinase-1

Letters in Drug Design and Discovery

Volumn 6, Issue 8, 2009, Pages 579-584

  Ramtekkar, Rahul ^a   Kumarvel, Kandhasamy ^a   Vasuki, Gnanasambandam ^a   Sekar, K ^b   Krishna, R ^a  

^a PONDICHERRY UNIVERSITY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Chk 1; Docking; Drug design; Glide; Oncology; Pyranopyrazoles

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHECKPOINT KINASE 1; COMPOUND PY00012; COMPOUND PY00021; COMPOUND PY00120; COMPOUND PY00199; COMPOUND PY02261; COMPOUND PY02384; CYSTEINE; GLUTAMIC ACID; LEUCINE; LIGAND; PYRANOPYRAZOLE DERIVATIVE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; COMPUTER AIDED DESIGN; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR INTERACTION; PRIORITY JOURNAL;

EID: 70349194675     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018009789353455     Document Type: Article

References (42)

1. Lowndes, N.F.; Murguia, J. R. Sensing and responding to DNA damage. Curr. Opin. Genet. Dev., 2000, 10, 17-25.
2. Clarke, D.J.; Gimenez-Abián, J.F. Checkpoints controlling mitosis. Bioessays, 2000, 22, 351-363.
3. Zhou, B.B.; Elledge, S.J. The DNA damage response: putting checkpoints in perspective. Nature, 2000, 408, 433-439.
4. Hartwell L.H.; Weinert, T.A. Checkpoints: controls that ensure the order of cell cycle events. Science, 1989, 246, 629-634.
5. Elledge, S.J. Cell cycle checkpoints: preventing an identity crisis. Science, 1996, 274, 1664-1672.
6. Rhind, N.; Russell, P. Mitotic DNA damage and replication checkpoints in yeast. Curr Opin. Cell Biol., 1998, 10, 749-758. (Pubitemid 28561021)
7. Graves, P.R.; Lijia, Y.; Schwarz, J.K.; Gales, J.; Sausville, E.A.; O'Conners, P.M.; Piwnica-Worms, H. The Chk1 protein kinase and the cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem., 2000, 275, 5600-5605. (Pubitemid 30115197)
8. Sanchez, Y.; Wong, C.; Thoma, R.S.; Richman, R.; Wu, Z.; Piwnica-Worms, H.; Elledge, S.J. Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25. Science, 1997, 277, 1497-1501.
9. Zachos, G.; Rainey, M.D.; Gillespie, D.A.F. Chk1-deficient tumor cells are viable but exhibit multiple checkpoint and survival defects. EMBO J., 2003, 22, 713-723.
10. Rhind, N.; Russell, P. Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways. J. Cell Sci., 2000, 113, 3889-3896.
11. 2/M DNA damage checkpoint. Genes Dev., 2000, 14, 1448-1459.
12. Chen, Z.; Xiao, Z.; Chen, J.; Ng, S.C.; Sowin, T.; Sham, H.; Rosenberg, S.; Fesik, S.; Zhang, H. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol. Cancer Ther., 2003, 2, 543-548.
13. Furnari, B.; Rhind, N.; Russell, P. Cdc25 mitotic inducer targeted by Chk1 DNA damage checkpoint kinase. Science, 1997, 277, 1495-1497. (Pubitemid 27449235)
14. Li, Q.; Zhu, G.D. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr. Top. Med. Chem., 2002, 2, 939-971.
15. Sausville, E.A.; Arbuck, S.G.; Messmann, R.; Headlee, D.; Bauer, K.S.; Lush, R.M.; Murgo, A.; Figg, W.D.; Lahusen, T.; Jaken, S.; jing, X.; Roberge, M.; Fuse, E.; Kuwabara, T.; Senderowicz, A.M. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol., 2001, 19, 2319-2333.
16. Senderowicz, A.M. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist, 2002, 7, 12-19.
17. Zhao, B.; Bower, M.J.; Mcdevitt, P.J.; Zhao, H.; Davis, S.T.; Johanson, K.O.; Green, S.M.; Concha, N.O.; Zhou, B.B. Structural basis of Chk1 inhibition by UCN-01. J. Biol. Chem., 2002, 277, 46609-46615.
18. Lyne, P.D.; Kenny, P.W., Cosgrove, D.A.; Deng, C.; Zabludoff, S.; Wendoloski, J.J.; Ashwell, S. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J. Med. Chem., 2004, 47, 1962-1968. (Pubitemid 38453915)
19. Busby, E.C.; Leistritz, D.F.; Abraham, R.T.; Karnitz, L.M.; Sarkaria, J. N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res., 2000, 60, 2108-2112.
20. Curman, D.; Cinel, B.; Williams, D.E.; Rundle, N.; Block, W.D.; Goodarzi, A.A.; Hutchins, J.R.; Clarke. P.R.; Zhou, B.B.; Lees-Miller, S.P.; Andersen, R.J., Roberge, M. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J. Biol. Chem., 2001, 276, 17914-17919. (Pubitemid 37411352)
21. Foloppe, N.; Fisher, L.M.; Howes, R.; Kierstan, P.; Potter, A.; Robertson, A.G.; Surgenor, A.E. Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity. J. Med. Chem., 2005, 48, 4332-4345.
22. Wang, G.T.; Li, G.; Mantei, R.A.; Chen, Z.; Kovar, P.; Gu, W.; Xiao, Z.; Zhang, H.; Sham, H.L.; Sowin, T.; Rosenberg, S.H.; Lin, N.H. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities. J. Med. Chem., 2005, 48, 3118-3121 (Pubitemid 40628030)
23. Lin, N.H.; Xia, P.; Kovar, P.; Park, C.; Chen Z.; Zhang, H.; Rosenberg, S.H.; Sham, H.L. Synthesis and biological evaluation of 3-ethylidine-1, 3-dihydro-indol-2-ones as noval checkpoint 1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 421-426.
24. Chen, P.; Luo, C.; Deng, Y.; Ryan, K.; Register, J.; Margosiak, S.; Tempczk-Russell, A.; Nguyen, B.; Myers, P.; Lundgren, K; Kan, C.C.; O'Conner, P.M. The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell, 2000, 17, 681-692.
25. Foloppe, N.; Fisher, L.M.; Francais, G.; Howes, R.; Kierstan, P.; Potter, A. Identification of a buried pocket and selective inhibition of Chk1: prediction and verification. Biorg. Med. Chem., 2006, 15, 1792-1804. (Pubitemid 43204311)
26. Foloppe, N.; Fisher, L.M.; Howes, R.; Potter, A.; Robertson, A.G.; Surgenor, A.E. Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening. Bioorg. Med. Chem., 2006, 14, 4792-4802.
27. Tong, Y.; Claiborne, A.; Stewart, K.D.; Park, C.; Kovar, P.; Chen, Z.; Credo, R.B.; Gu, W.Z.; Gwaltney, S.L. 2nd; Judge, R.A.; Zhang, H.; Rosenberg, S.H., Sham, H.L.; Sowin, T.J.; Lin, N.H. Discovery of 1,4-dihydroindeno[1,2-c] pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors. Bioorg. Med. Chem., 2007, 15, 2759-2767.
28. Ni, Z.J.; Barsanti, P.; Brammeier, N.; Diebes, A.; Poon, D.J.; NG, S.; Pecchi, S.; Pfister, K.; Renhowe, P.A.; Ramurthy, S.; Wagman, A.S.; Bussiere, D.E.; Le, V.; Zhou, Y.; Jansen, J.M.; Ma, S.; Gesner, T.G. 4-(Aminoalkylamino)- 3-benzimidazole-quinolinones as potent CHK-1 inhibitors. Bioorg. Med. Chem., 2006, 16, 3121-3124.
29. Lin, N.H.; Xia, P.; Kovar, P.; Park, C.; Chen, Z.; Zhang, H.; Rosenberg, S.H.; Sham, H.L. Synthesis and biological evaluation of 3-ethylidene-1,3- dihydro-indol-2-ones as novel checkpoint 1 inhibitors. Bioorg. Med. Chem Lett., 2006, 16, 421-426. (Pubitemid 41680639)
30. Huang, S.; Garbaccio, R.M.; Fraley, M.E.; Steen, J.; Kreatsoulas, C.; Hartman, G.; Stirdivant, S.; Drakas, B.; Rickert, K.; Walsh, E.; Hamilton, K.; Buser, C.A.; Hardwick, J.; Mao, X.; Abrams, M.; Beck, S.; Tao, W.; Lobell, R.; Sepp-Lorenzino, L.; Yan, Y.; Ikuta, M.; Murphy, J.Z.; Sardana, V.; Munshi, S.; Kuo, L.; Reilly, M.; Mahan, E. Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5907-5912. (Pubitemid 44486723)
31. Li, G.; Hasvold, L.A.; Tao, Z.F.; Wang, G.T.; Gwaltney II, S.L.; Patel, J.; Kovar, P.; Credo, R.B.; Chen, Z.; Zhang, H.; Park, C.; Sham, H.L.; Sowin, T.; Rosenberg, S.H.; Lin, N.H. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5- cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. Bioorg. Med. Chem, Lett. 2006, 16, 2293-2298.
32. Brnardic, E.J.; Garbaccio, R.M.; Fraley, M.E.; Tasber, E.S.; Steen, J.T.; Arrington, K.L.; Dudkin, V.Y.; Hartman, G.D.; Stirdivant, S.M.; Drakas, B.A.; Rickert, K.; Walsh, E.S.; Hamilton, K.; Buser, C.A.; Hardwick, J.; Tao, W.; Beck, S.C.; Mao, X.; Lobell, R.B.; Sepp-Lorenzino, L.; Yan, Y.; Ikuta, M.; Munshi, S.K.; Kuo, L.C.; Kreatsoulas, C. Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors. Bioorg. Med. Chem., Lett., 2007, 17, 5989-5994. (Pubitemid 47446196)
33. Abdelrazek, F.M.; Metz, P.; Kataeva, O.; Jäger, A.; El-Mahrouky, S.F. Synthesis and molluscicidal activity of new chromene and pyrano[2,3-c]pyrazole derivatives. Arch. Pharm. (Weinheim.), 2007, 340, 543-548. (Pubitemid 350007052)
34. Abdelrazek, F.M.; Metz, P.; Metwally, N.H.; El-Mahrouky, S.F. Synthesis and molluscicidal activity of new cinnoline and pyrano[2,3-c]pyrazole derivatives. Arch. Pharm. (Weinheim.), 2006, 339, 456-460 (Pubitemid 44320225)
35. Zaki, M.E.; Soliman, H.A.; Hiekal, O.A.; Rashad, A.E. Pyrazolopyranopyridines as a class of anti-inflammatory agents. Z Naturforsch C, 2006, 61, 1-5.
36. Witherington, J.; Bordas, V.; Garland, S.L.; Hickey, D.M.B.; Ife, R.J.; Liddle, J.; Saunders, M.; Smith, D.G.; Ward, R.W. 5-Arylpyrazolo[ 3,4-b]pyridines: Potent inhibitors of glycogen synthase kinases-3. Bioorg. Med. Chem. Lett., 2003, 13, 1577-1580. (Pubitemid 36428564)
37. Witherington, J.; Bordas, V.; Gaiba, A.; Naylor, A.; Rawlings, A.D.; Slingsby, B.P.; Smith, D.G.; Takle, A.K.; Ward, R.W. 6-Heteroaryl-pyrazolo [3,4-b]pyridines: Potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett., 2003, 13, 3059-3062. (Pubitemid 36993636)
38. Lin, R.; Connolly, P.J.; Lu, Y.; Chiu, G.; Li, S.; Yu, Y.; Huang, S.; Li, X.; Emanuel, S.L.; Middleton, S.A.; Gruninger, R.H.; Adams, M.; Fuentes-Pesquera, A.R.; Greenberger, L.M. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as antitumor agents. Bioorg. Med. Chem. Lett., 2007, 17, 4297-4302. (Pubitemid 47021391)
39. Vasuki, G.; Kumarvel. K. Rapid four-component reactions in water: synthesis of pyranopyrazoles. Tetrahedron let., 2008, 49, 5636-5638.
40. Protein Data Bank. An Information Portal to Biological Macromolecular Structures. http://www.rcsb.org/pdb/explore/explore.do? structureId=1ZYS [Accessed August 4, 2003].
41. Shelley, J.C.; Cholleti, A.; Frye, L.L.; Greenwood, J.R.; Timlin, M.R.; Uchimaya, M. Epik: a software program for pK (a) prediction and protonation state generation for drug-like molecules. J. Comput. Aided. Mol. Des., 2007, 21, 681-691.
42. Jorgensen, W.L.; Maxwell, D.S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118, 11225-11236.